An observational study in Respiratory Infections in Old Age, sponsored by University Hospital, Grenoble. Recruiting at 24 sites in 5 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by University Hospital, Grenoble · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Respiratory Tract Infections with a site in Italy — 11 open to participants now, 13 under way, 2 of them phase 3. Respiratory Tract Infections · Italy.
Among the 34 studies in Respiratory Tract Infections with a site in Italy, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2026, is one of 10 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 32nd registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.
Browse Respiratory Tract Infections studies →11 of the 34 studies in Respiratory Tract Infections with a site in Italy are open now. Recruiting first, the newest first:
Azienda Ospedaliero-Universitaria Careggi · Sites in Italy
Ages 18–90
Laboratorio Farmaceutico SIT srl · Sites in Italy, North Macedonia
Ages 18–99
Campus Bio-Medico University · Sites in Italy
Ages 75+
Cardarelli Hospital · Sites in Italy
Ages 18+
AstraZeneca · Sites in Italy, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 60 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,600 is above the median of 350 across 184 observational studies indexed under Respiratory Tract Infections.
Median enrollment 252 across the 23 interventional studies, 700 across the 10 observational. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 34 have an industry lead sponsor. The 10 most frequent:
University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
University Hospital, Grenoble has 2 studies filed under Respiratory Tract Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Respiratory Tract Infections with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06736288Laboratorio Farmaceutico SIT srlPost Authorization Efficacy and Safety Study (PAES) to Confirm and Collect More Clinical Data of Buccalin® Tablets In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIs). | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 34 studies in Respiratory Tract Infections with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The prevention of infectious diseases in older adults remains a major public health challenge, as acute respiratory infections are a leading cause of hospitalisation, mortality, and functional decline worldwide. Immunosenescence and environmental exposures increase susceptibility to infection and reduce vaccine effectiveness in this population. Respiratory viruses, including influenza, SARS-CoV-2, respiratory syncytial virus, and human metapneumovirus, account for a substantial share of this burden, much of which is vaccine-preventable. However, their impact on functional decline and recovery in older adults remains insufficiently characterized. This international study aims to assess the effect of hospitalization for major respiratory viral infections on loss of autonomy in individuals aged 60 years and older, to inform targeted prevention and vaccination strategies.
The prevention of infectious diseases in older adults represents a major public health challenge due to their substantial impact on morbidity, mortality, and loss of functional capacity. Acute respiratory infections are among the leading causes of hospitalization and death in this population worldwide.
Ageing is associated with a progressive decline in immune function, resulting in increased susceptibility to infections and reduced vaccine effectiveness. In addition, environmental factors such as residence in collective living settings and repeated exposure to healthcare environments further increase the risk of exposure to and transmission of infectious agents.
The pathogens most frequently involved include respiratory viruses namely influenza, SARS-CoV-2, respiratory syncytial virus, and human metapneumovirus as well as bacterial pathogens, particularly Streptococcus pneumoniae, and certain fungal agents. A substantial proportion of these infections are potentially preventable through vaccination.
Despite advances generated by the European IMI VITAL project and the AEQUI case-control study, data remain limited regarding the functional consequences of acute respiratory infections in older adults, particularly their impact on dependency, frailty, and post-infectious recovery.
This international study aims to address these knowledge gaps by evaluating the impact of hospitalizations related to influenza, SARS-CoV-2, respiratory syncytial virus, and human metapneumovirus on loss of autonomy in individuals aged 60 years and older. The findings are expected to strengthen the scientific evidence base needed to inform targeted vaccination and prevention strategies, ultimately contributing to healthier ageing.
The study population will include participants aged 60 years or older who are hospitalized with a serious acute respiratory infection in the departments of infectious diseases, geriatrics, internal medicine, pulmonology, or emergency medicine. Recruitment will be conducted by investigator physicians in each participating department. Potentially eligible participants will be identified by daily screening of admission records and results from standard of care respiratory samples.
Each country will aim to recruit approximately 320 participants - 80 with each pathogen of interest. Efforts will be made to secure an equal distribution of participants aged 60-75 and >75 years age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Evolution of Functional Dependency assessed by Activities of Daily Living (ADL) Score
Change in functional performance measured using the Activities of Daily Living (ADL) scale. The ADL score ranges from 0 to 6, where higher scores indicate better functional independence The ADL score ranges from 0 to 6, where higher scores indicate better functional independence.
Time frame: Baseline, at hospital discharge, 3 months after discharge, and 6 months after discharge.
Evolution of Functional Dependency assessed by Instrumental Activities of Daily Living (IADL) Score
Change in functional performance measured using the Instrumental Activities of Daily Living (IADL) scale. The IADL score ranges from 0 to 8, where higher scores indicate better functional independence.
Time frame: Baseline, Day 7, 3 months after discharge, and 6 months after discharge.
Functional Status depending on Viral Etiology Assessed by Activities of Daily Living (ADL) Score
Change in functional status measured using the Activities of Daily Living (ADL) scale. The ADL score ranges from 0 to 6, where higher scores indicate better functional independence. Changes in score will be assessed between baseline, hospital discharge, 3 months, and 6 months, and stratified by viral etiology (SARS-CoV-2, influenza, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV)).
Time frame: Baseline, Day 7, 3 months after discharge, and 6 months after discharge.
Functional Status depending on Viral Etiology Assessed by Instrumental Activities of Daily Living (IADL) Score
Change in functional status measured using the Instrumental Activities of Daily Living (IADL) scale. The IADL score ranges from 0 to 8, where higher scores indicate better functional independence. Changes in score will be assessed between baseline, hospital discharge, 3 months, and 6 months, and stratified by viral etiology (SARS-CoV-2, influenza, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV)).
Time frame: Baseline, Day 7, 3 months after discharge, and 6 months after discharge.
Medical Complications during and after hospitalization
Occurrence of medical complications during hospitalization and up to 6 months after discharge, including new diagnoses identified during follow-up.
Time frame: From hospital admission to 6 months after discharge.
Health Care Resource Utilization (HCRU)
Health care resource utilization, including hospital length of stay, intensive care unit (ICU) admission during index hospitalization, and hospital readmissions occurring between discharge and 6 months.
Time frame: From hospital admission to 6 months after discharge.
Length of Hospital Stay
Duration of the index hospitalization, measured in days, calculated from hospital admission (Day 1) to hospital discharge.
Time frame: 3 months after discharge
Intensive Care Unit (ICU) Admission
Proportion of participants admitted to an intensive care unit during the index hospitalization.
Time frame: 3 months after hospital discharge.
Hospital Readmissions After Discharge
Occurrence of hospital readmissions between discharge and 6 months after discharge.
Time frame: From at hospital discharge to 6 months after discharge.
New Medications Initiated
Initiation of new drug treatments during hospitalization or within 6 months after discharge.
Time frame: From hospital admission to 6 months after discharge.
Discharge Location after Hospitalization
Location at hospital discharge (e.g., home, rehabilitation facility, long-term care facility).
Time frame: 3 months after hospital discharge.
Living Situation at 6 Months after Discharge
Living situation of participants at 6 months after hospital discharge
Time frame: 6 months after hospital discharge.
Demographic Characteristics of Participants
Baseline demographic characteristics of participants, including age and sex.
Time frame: Baseline.
Living Situation at Baseline
Living situation of participants prior to hospital admission.
Time frame: Baseline.
Prevalence of Comorbidities
Prevalence of pre-existing comorbidities at baseline.
Time frame: Baseline.
Vaccination Status
Proportion of participants vaccinated against influenza, SARS-CoV-2, and respiratory syncytial virus (RSV).
Time frame: Baseline.
Time since last vaccination
Time elapsed since the most recent vaccination against influenza, SARS-CoV-2, or RSV, measured in months.
Time frame: Baseline.
Pneumonia Severity Index (PSI) Score
Severity of pneumonia assessed using the Pneumonia Severity Index (PSI) score at hospital admission.
Time frame: Baseline
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2028, 24 months after the start.
Of 67 non-industry observational studies under Respiratory Tract Infections, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 24 months is close to that.
Counting every sponsor, half of 86 studies reached it within 18 months; a quarter within 8 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Tract Infections →
University Hospital, Grenoble →